December 7–10, 2021 | Henry B. Gonzalez Convention Center | San Antonio, TX

Loading Events

« All Events

  • This event has passed.

Cerianna: Seeing Deeper into Recurrent or Metastatic Breast Cancer

December 7, 2021 @ 10:00 am - 11:00 am CST

Sponsored by GE Healthcare

Program Description

You’re invited to attend a complimentary Product Theater sponsored by GE Healthcare, “Seeing Deeper into Recurrent or Metastatic Breast Cancer” on Tuesday, December 7, 2021 at 10:00am presented by Hannah Linden, MD, Professor, Division of Medical Oncology, University of Washington School of Medicine, Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center and Gary Ulaner, MD, PhD, FACNM, James & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy, Hoag Family Cancer Institute During this Product Theater, Dr. Linden will discuss unmet needs and review clinical outcomes with F18 Fluoroestradiol and Dr. Ulaner will present potential application by identifying patients that may benefit from a Cerianna PET/CT.

Presentation objectives:

  • Learn about the clinical implications of Estrogen Receptor discordance
  • Understand the mechanism of Cerianna PET imaging
  • Recognize the clinical applications of Cerianna PET imaging
  • Identify patients who may benefit from Cerianna PET imaging

This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium®.

Important Safety Information

Indications and Usage

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

Limitations of Use

Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR).
Contraindications: None.
Adverse Reactions: In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate <1%: were injection-site pain and dysgeusia.


For full Prescribing Information click on or visit


December 7, 2021
10:00 am - 11:00 am CST
Event Category:

© 2021 SABCS. All Rights Reserved. Powered By TriStar Event Media, LLC